• 1
    Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care 2004;27:145886.
  • 2
    Boulton AJ, Vinik AI, Arezzo JC, et al. American Diabetes Association. Diabetic neuropathies: A statement by the American Diabetes Association. Diabetes Care 2005;28:95662.
  • 3
    Veves A, Manes C, Murray HJ, Young MJ, Boulton AJ. Painful neuropathy and foot ulceration in diabetic patients. Diabetes Care 1993;16:11879.
  • 4
    Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: Epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000;47:1238.
  • 5
    Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 2003;26:17905.
  • 6
    Ziegler D, Gries FA, Spuler M, Lessmann F. The epidemiology of diabetic neuropathy. Diabetic Cardiovascular Autonomic Neuropathy Multicenter Study Group. J Diabetes Complications 1992;6:4957.
  • 7
    Sumner CJ, Sheth S, Griffin JW, Cornblath DR, Polydefkis M. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 2003;60:10811.
  • 8
    Malik RA, Veves A, Walker D, et al. Sural nerve fibre pathology in diabetic patients with mild neuropathy: Relationship to pain, quantitative sensory testing and peripheral nerve electrophysiology. Acta Neuropathol (Berl) 2001;101:36774.
  • 9
    Britland ST, Young RJ, Sharma AK, Clarke BF. Acute and remitting painful diabetic polyneuropathy: A comparison of peripheral nerve fibre pathology. Pain 1992;48:36170.
  • 10
    Britland ST, Young RJ, Sharma AK, Clarke BF. Association of painful and painless diabetic polyneuropathy with different patterns of nerve fiber degeneration and regeneration. Diabetes 1990;39:898908.
  • 11
    Veves A, Young MJ, Manes C, Boulton AJ. Differences in peripheral and autonomic nerve function measurements in painful and painless neuropathy. A clinical study. Diabetes Care 1994;17:12002.
  • 12
    Sorensen L, Molyneaux L, Yue DK. The level of small nerve fiber dysfunction does not predict pain in diabetic neuropathy: A study using quantitative sensory testing. Clin J Pain 2006;22:2615.
  • 13
    Sorensen L, Molyneaux L, Yue DK. The relationship among pain, sensory loss, and small nerve fibers in diabetes. Diabetes Care 2006;29:8837.
  • 14
    Baron R. Peripheral neuropathic pain: From mechanisms to symptoms. Clin J Pain 2000; 16:S12S20.
  • 15
    Scadding JW. Development of ongoing activity, mechanosensitivity, and adrenaline sensitivity in severed peripheral nerve axons. Exp Neurol 1981;73:34564.
  • 16
    Woolf CJ, Shortland P, Coggeshall RE. Peripheral nerve injury triggers central sprouting of myelinated afferents. Nature 1992;355:758.
  • 17
    Tsigos C, Reed P, Weinkove C, White A, Young RJ. Plasma norepinephrine in sensory diabetic polyneuropathy. Diabetes Care 1993;16:7227.
  • 18
    Wall PD, Gutnick M. Ongoing activity in peripheral nerves: The physiology and pharmacology of impulses originating from a neuroma. Exp Neurol 1974;43:58093.
  • 19
    Seltzer Z, Devor M. Ephaptic transmission in chronically damaged peripheral nerves. Neurology 1979;29:10614.
  • 20
    Tack CJ, Van Gurp PJ, Holmes C, Goldstein DS. Local sympathetic denervation in painful diabetic neuropathy. Diabetes 2002;51:354553.
  • 21
    Quattrini C, Harris ND, Malik RA, Tesfaye S. Impaired skin microvascular reactivity in painful diabetic neuropathy. Diabetes Care 2007;30:6559.
  • 22
    Spruce MC, Potter J, Coppini DV. The pathogenesis and management of painful diabetic neuropathy: A review. Diabet Med 2003;20:8898.
  • 23
    Schmeichel AM, Schmelzer JD, Low PA. Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. Diabetes 2003;52:16571.
  • 24
    Stanfa LC, Dickenson AH. The role of non-N-methyl-D-aspartate ionotropic glutamate receptors in the spinal transmission of nociception in normal animals and animals with carrageenan inflammation. Neuroscience 1999;93:13918.
  • 25
    Svendsen F, Tjolsen A, Hole K. AMPA and NMDA receptor-dependent spinal LTP after nociceptive tetanic stimulation. Neuroreport 1998;9:118590.
  • 26
    Calcutt NA. Potential mechanisms of neuropathic pain in diabetes. Int Rev Neurobiol 2002;50:20528.
  • 27
    Selvarajah D, Wilkinson ID, Emery CJ, et al. Early involvement of the spinal cord in diabetic peripheral neuropathy. Diabetes Care 2006;29:26649.
  • 28
    Archer AG, Watkins PJ, Thomas PK, Sharma AK, Payan J. The natural history of acute painful neuropathy in diabetes mellitus. J Neurol Neurosurg Psychiatry 1983;46:4919.
  • 29
    Boulton AJ, Armstrong WD, Scarpello JH, Ward JD. The natural history of painful diabetic neuropathy—a 4-year study. Postgrad Med J 1983;59:5569.
  • 30
    Benbow SJ, Chan AW, Bowsher D, MacFarlane IA, Williams G. A prospective study of painful symptoms, small-fibre function and peripheral vascular disease in chronic painful diabetic neuropathy. Diabet Med 1994;11:1721.
  • 31
    Caselli A, Rich J, Hanane T, Uccioli L, Veves A. Role of C-nociceptive fibers in the nerve axon reflex-related vasodilation in diabetes. Neurology 2003;60:297300.
  • 32
    Smith AG, Ramachandran P, Tripp S, Singleton JR. Epidermal nerve innervation in impaired glucose tolerance and diabetes-associated neuropathy. Neurology 2001;57:17014.
  • 33
    Smith AG, Russell J, Feldman EL, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care 2006;29:12949.
  • 34
    Zelman D, Gore M, Dukes E. Validation of a Modified Version of the Brief Pain Inventory for Painful Diabetic Peripheral Neuropathy. J Pain Symptom Manage 2005;29:40110.
  • 35
    Krause SJ, Backonja MM. Development of a neuropathic pain questionnaire. Clin J Pain 2003;19:30614.
  • 36
    Backonja MM, Krause SJ. Neuropathic pain questionnaire—short form. Clin J Pain 2003;19:3156.
  • 37
    Bouhassira D, Attal N, Alchaar H, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 2005;114:2936.
  • 38
    Bouhassira D, Attal N, Fermanian J, et al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain 2004;108:24857.
  • 39
    Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: The Neuropathic Pain Scale. Neurology 1997;48:3328.
  • 40
    The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995;122:5618.
  • 41
    Amthor KF, Dahl-Jorgensen K, Berg TJ, et al. The effect of 8 years of strict glycaemic control on peripheral nerve function in IDDM patients: The Oslo Study. Diabetologia 1994;37:57984.
  • 42
    Tesfaye S, Stevens LK, Stephenson JM, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: The EURODIAB IDDM Complications Study. Diabetologia 1996;39:137784.
  • 43
    UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:83753.
  • 44
    Oyibo SO, Prasad YD, Jackson NJ, Jude EB, Boulton AJ. The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: A pilot study. Diabet Med 2002;19: 8703.
  • 45
    Boulton AJ, Drury J, Clarke B, Ward JD. Continuous subcutaneous insulin infusion in the management of painful diabetic neuropathy. Diabetes Care 1982;5:38690.
  • 46
    Gore M, Dukes E, Rowbotham DJ, Tai KS, Leslie D. Clinical characteristics and pain management among patients with painful peripheral neuropathic disorders in general practice settings. Eur J Pain 2007;11:65264.
  • 47
    Sindrup S, Otto M, Finnerup N. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol 2005;96:399409.
  • 48
    Dick IE, Brochu RM, Purohit Y, et al. Sodium channel blockade may contribute to the analgesic efficacy of antidepressants. J Pain 2007;8:31524.
  • 49
    Max MB, Culnane M, Schafer SC, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987;37:58996.
  • 50
    Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992;326:12506.
  • 51
    Vrethem M, Boivie J, Arnqvist H, et al. A comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics. Clin J Pain 1997;13:31323.
  • 52
    Kvinesdal B, Molin J, Froland A, Gram LF. Imipramine treatment of painful diabetic neuropathy. JAMA 1984;251:172730.
  • 53
    Sindrup SH, Ejlertsen B, Froland A, et al. Imipramine treatment in diabetic neuropathy: Relief of subjective symptoms without changes in peripheral and autonomic nerve function. Eur J Clin Pharmacol 1989;37:1513.
  • 54
    Sindrup SH, Gram LF, Skjold T, Grodum E, Brosen K, Beck-Nielsen H. Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double-blind cross-over study. Br J Clin Pharmacol 1990;30:68391.
  • 55
    Max MB, Kishore-Kumar R, Schafer SC et al. Efficacy of desipramine in painful diabetic neuropathy: A placebo-controlled trial. Pain 1991;45:39.
  • 56
    McQuay H, Tramer M, Nye BA. A systematic review of antidepressants in neuropathic pain. Pain 1996;68:21727.
  • 57
    Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2005:CD005454.
  • 58
    Sindrup SH, Gram LF, Brosen K, Eshoj O, Mogensen EF. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990;42:13544.
  • 59
    Sindrup SH, Bjerre U, Dehgaard A, et al. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther 1992;52:54752.
  • 60
    New drug for neuropathic pain. FDA Consum 2004;38(6):2.
  • 61
    Wernicke JF, Gahimer J, Yalcin I, Wulster-Radcliffe M, Viktrup L. Safety and adverse event profile of duloxetine. Expert Opin Drug Saf 2005;4:98793.
  • 62
    Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005;6:34656.
  • 63
    Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005;116:10918.
  • 64
    Wernicke JF, Pritchett YL, D’Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006;67:141120.
  • 65
    Raskin J, Smith TR, Wong K, et al. Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain. J Palliat Med 2006;9:2940.
  • 66
    Raskin J, Wang F, Pritchett YL, Goldstein DJ. Duloxetine for patients with diabetic peripheral neuropathic pain: A 6-month open-label safety study. Pain Med 2006;7:37385.
  • 67
    Hardy T, Sachson R, Shen S, Armbruster M, Boulton AJ. Does treatment with duloxetine for neuropathic pain impact glycemic control? Diabetes Care 2007;30:216.
  • 68
    Ziegler D, Pritchett YL, Wang F, et al. Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain. Diabetes Care 2007;30:6649.
  • 69
    Guldiken S, Guldiken B, Arikan E, et al. Complete relief of pain in acute painful diabetic neuropathy of rapid glycaemic control (insulin neuritis) with venlafaxine HCL. Diabetes Nutr Metab 2004;17:2479.
  • 70
    Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: A double-blind, placebo-controlled study. Pain 2004;110:697706.
  • 71
    McQuay H, Carroll D, Jadad AR, et al. Anticonvulsant drugs for the management of pain: A systematic review. BMJ 1995;311:104752.
  • 72
    Jensen TS. Anticonvulsants in neuropathic pain: Rationale and clinical evidence. Eur J Pain 2002;6:618.
  • 73
    Wiffen P, Collins S, McQuay H, et al. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev 2005;20:CD001133.
  • 74
    Wiffen PJ, McQuay HJ, Moore RA. Carbamazepine for acute and chronic pain. Cochrane Database Syst Rev 2005:CD005451.
  • 75
    Dogra S, Beydoun S, Mazzola J, Hopwood M, Wan Y. Oxcarbazepine in painful diabetic neuropathy: A randomized, placebo-controlled study. Eur J Pain 2005;9:54354.
  • 76
    Beydoun A, Shaibani A, Hopwood M, Wan Y. Oxcarbazepine in painful diabetic neuropathy: Results of a dose-ranging study. Acta Neurol Scand 2006;113:395404.
  • 77
    Grosskopf J, Mazzola J, Wan Y, Hopwood M. A randomized, placebo-controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurol Scand 2006;114:17780.
  • 78
    Backonja M, Beydoun A, Edwards KR et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: A randomized controlled trial. JAMA 1998;280:18316.
  • 79
    Wiffen PJ, McQuay HJ, Edwards JE, Moore RA. Gabapentin for acute and chronic pain. Cochrane Database Syst Rev 2005:CD005452.
  • 80
    Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: Evidence from randomized placebo controlled clinical trials. Clin Ther 2003;25:81104.
  • 81
    Sonnett TE, Setter SM, Campbell RK. Pregabalin for the treatment of painful neuropathy. Expert Rev Neurother 2006;6:162935.
  • 82
    Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: A double-blind, placebo-controlled trial. Pain 2004; 110:62838.
  • 83
    Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: A randomized controlled trial. Neurology 2004;14:210410.
  • 84
    Richter RW, Portenoy R, Sharma U, LaMoreaux L, Bockbrader H, Knapp LE. Relief of painful diabetic peripheral neuropathy with pregabalin: A randomized, placebo-controlled trial. J Pain 2005;6:25360.
  • 85
    Vinik AI, Tuchman M, Safirstein B, et al. Lamotrigine for treatment of pain associated with diabetic neuropathy: Results of two randomized, double-blind, placebo-controlled studies. Pain 2007;128:16979.
  • 86
    Eisenberg E, McNicol E, Carr DB. Opioids for neuropathic pain. Cochrane Database Syst Rev 2006: CD006146.
  • 87
    Eisenberg E, McNicol ED, Carr DB. Efficacy of mu-opioid agonists in the treatment of evoked neuropathic pain: Systematic review of randomized controlled trials. Eur J Pain 2006;10:66776.
  • 88
    Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998;50:18426.
  • 89
    Harati Y, Gooch C, Swenson M, et al. Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy. J Diabetes Complications 2000;14:6570.
  • 90
    Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: A randomized controlled trial in painful diabetic neuropathy. Pain 2003;105:718.
  • 91
    Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005;352:132434.
  • 92
    Dejgard A, Petersen P, Kastrup J. Mexiletine for treatment of chronic painful diabetic neuropathy. Lancet 1988;1:911.
  • 93
    Stracke H, Meyer UE, Schumacher HE, Federlin K. Mexiletine in the treatment of diabetic neuropathy. Diabetes Care 1992;15:15505.
  • 94
    Oskarsson P, Ljunggren JG, Lins PE. Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy. The Mexiletine Study Group. Diabetes Care 1997;20:15947.
  • 95
    McCartney CJ, Sinha A, Katz J. A qualitative systematic review of the role of N-methyl-D-aspartate receptor antagonists in preventive analgesia. Anesth Analg 2004;98:1385400.
  • 96
    Nelson KA, Park KM, Robinovitz E, Tsigos C, Max MB. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and post herpetic neuralgia. Neurology 1997;48:12128.
  • 97
    Sang CN, Booher S, Gilron I, Parada S, Max MB. Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: Efficacy and dose–response trials. Anesthesiology 2002;96:105361.
  • 98
    Thisted RA, Klaff L, Schwartz SL, et al. Dextromethorphan and quinidine in adult patients with uncontrolled painful diabetic peripheral neuropathy: A 29-day, multicenter, open-label, dose-escalation study. Clin Ther 2006;28:160718.
  • 99
    Yuen KC, Baker NR, Rayman G. Treatment of chronic painful diabetic neuropathy with isosorbide dinitrate spray: A double-blind placebo-controlled crossover study. Diabetes Care 2002;25:1699703.
  • 100
    Rayman G, Baker NR, Krishnan ST. Glyceryl trinitrate patches as an alternative to isosorbide dinitrate spray in the treatment of chronic painful diabetic neuropathy. Diabetes Care 2003;26:26978.
  • 101
    Zhang WY, Wan Po AL. The effectiveness of topically applied capsaicin: A meta-analysis. Eur J Clin Pharmacol 1994;45:51722.
  • 102
    Polydefkis M, Hauer P, Sheth S, et al. The time course of epidermal nerve fibre regeneration: Studies in normal controls and in people with diabetes, with and without neuropathy. Brain 2004;127:160615.
  • 103
    Abuaisha BB, Constanzi JB, Boulton AJM. Acupuncture for the treatment of chronic painful diabetic neuropathy: A long-term study. Diabetes Res Clin Pract 1998;39:11521.
  • 104
    Hamza MA, White PF, Craig WF, et al. Percutaneous electrical nerve stimulation: A novel analgesic therapy for diabetic neuropathic pain. Diabetes Care 2000;23:36570.
  • 105
    Weintraub MI, Wolfe GI, Barohn RA, et al. Static magnetic field therapy for symptomatic diabetic neuropathy; a randomized, double-blind, placebo-controlled trial. Arch Phys Med Rehabil 2003; 86:73646.
  • 106
    Tesfaye S, Watt J, Benbow SJ, et al. Electrical spinal-cord stimulation for painful diabetic peripheral neuropathy. Lancet 1996;348:1698701.
  • 107
    Valdivia JM, Dellon AL, Weinand ME, Maloney CT Jr. Surgical treatment of peripheral neuropathy: Outcomes from 100 consecutive decompressions. J Am Podiatr Med Assoc 2005;95:4514.
  • 108
    Chaudhry V, Stevens JC, Kincaid J, So YT. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Practice Advisory: Utility of surgical decompression for treatment of diabetic neuropathy: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2006;66:18058.
  • 109
    Reljanovic M, Reichel G, Rett K, et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): A two year multicentre randomized double-blind placebo-controlled trial (ALADIN II). Free Radic Res 1999;31:1719.
  • 110
    Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: A 7-month multicentre randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Diabetes Care 1999;22:1296301.
  • 111
    Ametov AS, Barinov A, Dyck PJ, et al. SYDNEY Trial Study Group. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: The SYDNEY trial. Diabetes Care 2003;26:7706.
  • 112
    Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: The SYDNEY 2 trial. Diabetes Care 2006;29:236570.
  • 113
    Argoff CE, Backonja MM, Belgrade MJ, et al. Consensus guidelines: Treatment planning and options. Diabetic peripheral neuropathic pain. Mayo Clin Proc 2006;81(4 Suppl.):S1225.
  • 114
    Jensen TS, Backonja MM, Hernandez Jimenez S, et al. New perspectives on the management of diabetic peripheral neuropathic pain. Diab Vasc Dis Res 2006;3:10819.
  • 115
    Backonja M-M, Irving GA, Argoff CE. Rational multidrug therapy in the treatment of neuropathic pain. Curr Pain Headache Rep 2006;10: 348.